Forbes Medi-Tech Initiates US Phase II Trial For Cholesterol-Lowering Drug, FM-VP4

VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 2, 2005--Forbes Medi-Tech Inc. (NASDAQ:FMTI)(TSX:FMI) today announced that it has initiated its US Phase II trial for its cholesterol-lowering drug, FM-VP4. Fifteen US sites have been selected and have begun to identify potentially eligible subjects. The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12.

MORE ON THIS TOPIC